<DOC>
	<DOCNO>NCT01313624</DOCNO>
	<brief_summary>The AIR-BX1 study enrol people non-cystic fibrosis ( non-CF ) bronchiectasis gram-negative airway infection . Participants receive two 28-day course either Aztreonam Inhalation Solution ( AZLI ) placebo take 3 time day . Each course follow 28-day off-drug period . Following two blinded course , participant receive 28-day course open-label AZLI follow additional 56 day .</brief_summary>
	<brief_title>Safety Effectiveness AZLI ( Inhaled Antibiotic ) Adults With Non-Cystic Fibrosis Bronchiectasis</brief_title>
	<detailed_description />
	<mesh_term>Bronchiectasis</mesh_term>
	<criteria>Male/Female 18 year old nonCF bronchiectasis Chronic sputum production day Positive sputum culture gramnegative organism Must meet lung function requirement History CF Hospitalized within 14 day prior join study Previous exposure AZLI Pregnant , breastfeeding , unwilling follow contraceptive measure study Must meet liver kidney function requirement Continuous oxygen use great 2 liter per minute ( supplemental oxygen activity night allow ) Treatment nontuberculous mycobacteria infection active mycobacterium tuberculosis infection within 1 year enrollment Other serious medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>